UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 13, 2021
Synaptogenix, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40458 | 46-1585656 |
(State or other jurisdiction
of incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (973) 242-0005
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading
Symbol(s) | | Name of each exchange on which
registered |
| Common Stock, $0.0001 par value per share | | SNPX | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company. x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 13, 2021 (the “Grant Date”), upon recommendation of the compensation committee, the board of directors (the “Board”) of Synaptogenix, Inc. (the “Company”) approved a one-time grant of restricted stock units (“RSU”), to the following members of the Board and management in light of their efforts made in connection with the previously disclosed spin-off, up-listing of the Company’s shares of common stock to The Nasdaq Capital Market and the previously disclosed private placement financing which was completed in June 2021:
| Name: | | Number of RSUs: | |
| Joshua N. Silverman | | | 90,000 | |
| Daniel Alkon, M.D. | | | 80,000 | |
| Alan J. Tuchman, M.D. | | | 60,000 | |
| Robert Weinstein | | | 60,000 | |
| William S. Singer | | | 60,000 | |
| Bruce T. Bernstein | | | 50,000 | |
| Jonathan L. Schechter | | | 45,000 | |
| George Perry, Ph.D. | | | 40,000 | |
The RSUs vest 50% on the six month anniversary of the Grant Date and the remaining 50% on the one-year anniversary of the Grant Date and are subject to such other terms and conditions provided in the Company’s 2020 Equity Incentive Plan and the form of restricted stock unit agreement approved by the Board, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 16, 2021 | By: | /s/ Robert Weinstein |
| | Name: | Robert Weinstein |
| | Title: | Chief Financial Officer |
